GSGuruprasadh Swaminathan

Guruprasadh Swaminathan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Guruprasadh Swaminathan has a total of 28 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Cell-specific FUS loss enhances ageing-associated transcriptional elongation in lung fibrosis

    by Diana G. Rogel-Ayala, Julio Cordero, Héctor A. Aguirre-Alarcón, Karla Rubio, Guruprasadh Swaminathan, Naceur Charif, Natalia de Isla, Witold Szymanski, Gowthami Kolluru Venkataswamy Reddy, Peter Braubach, et al.

    Summary: Idiopathic pulmonary fibrosis (IPF) is an age-related, lethal lung disease affecting over 3 million people worldwide. During aging, impairment of diverse molecular processes compromises cellular homeostasis. Eukaryotic cells adapt to this ageing-associated stress by large-scale transcriptome changes affecting the expression of genes involved in signaling, protein homeostasis, cell plasticity and immune response. The molecular mechanisms regulating extensive transcriptome rearrangements leading to senescence in specific cell types of IPF lungs remain sparely investigated. Here we uncover fundamental molecular mechanisms underlying cellular senescence by integrative analysis of multi-omics studies and functional experiments monitoring fibrotic and senescence hallmarks in primary lung fibroblasts from control and IPF patients. Loss-of-function of the DNA/RNA binding protein fused in sarcoma (FUS) in control fibroblasts enhanced fibrotic and senescence hallmarks resembling IPF fibroblasts. Dissecting the molecular mechanisms, reduced FUS levels in IPF fibroblasts abolished R-loop formation at transcription start sites (TSS), leading to increased RNA polymerase II (Pol II) recruitment and its phosphorylation at serine 2, resulting in enhanced translocation speed of elongating Pol II and increased expression of fibrosis-and senescence-related genes. Summarizing, FUS maintains low Pol II processivity in control fibroblasts by stabilizing R-loops at TSS, acting as a gatekeeper of fibrotic and age-associated transcriptional programs.

  • Erlotinib induces 3D genome rearrangements in lung cancer cells activating tumor suppressor genes through FOXA2-bound Epromoters

    by Guruprasadh Swaminathan

    L'erlotinib induit des réarrangements du génome en 3D dans les cellules cancéreuses du poumon activant les gènes suppresseurs de tumeurs par l'intermédiaire d'épromoteurs liés à FOXA2: Le cancer du poumon non à petites cellules (CPNPC) est le type de cancer du poumon (PC) le plus fréquent et son traitement reste un défi mondial. Bien que l'erlotinib soit un inhibiteur de la tyrosine kinase (ITK) du récepteur du facteur de croissance épidermique (EGFR) approuvé par la FDA et utilisé dans le traitement du CPNPC, la manière dont le médicament affecte le paysage génomique et épigénomique n'est toujours pas claire. Nous avons réalisé des études multi-omiques intégratives pour élucider les mécanismes épigénétiques induits par l'erlotinib dans les cellules de carcinome pulmonaire humain. Nous avons identifié 746 gènes (dont 34 gènes suppresseurs de tumeurs, TSG) qui étaient régulés à la hausse après un traitement à l'erlotinib dans les cellules A549 (cellules épithéliales alvéolaires basales humaines dérivées d'un adénocarcinome pulmonaire). Ces résultats ont été confirmés dans les cellules PC-9 (lignée cellulaire d'adénocarcinome pulmonaire humain) également traitées à l'erlotinib ou au géfitinib (un autre EGFR-TKI). Parmi les 746 gènes régulés à la hausse, 45 % (dont 24 TSG) se trouvaient dans de larges domaines de la marque histonique euchromatinienne H3K4me3, et 63 % (dont 26 TSG) présentaient des niveaux réduits de la marque histonique hétérochromatinienne H3K27me3 après le traitement à l'erlotinib. En outre, les méthodes de capture de la conformation des chromosomes spécifiques à H3K27ac ont révélé que le traitement par l'erlotinib augmentait de manière significative le nombre et la longueur des boucles de chromatine entre les promoteurs de 605 gènes régulés à la hausse (81 %, dont 34 TSG) et les enhancers ou super-enhancers typiques. Il est intéressant de noter que les ancres de ces boucles chromatiniennes sont enrichies de CTCF (CCCTC-binding factor) et du complexe de cohésine. En outre, nous avons détecté une augmentation de l'accessibilité de la chromatine après le traitement par erlotinib au niveau des promoteurs des gènes régulés par l'analyse de la chromatine accessible à la transposase par séquençage (ATAC-seq), en corrélation avec la liaison de l'activateur de la transcription FOXA2. La pertinence clinique de nos résultats a été confirmée par l'analyse des données déposées dans l'Atlas du génome du cancer, montrant des résultats de survie significativement améliorés chez les patients atteints de PC présentant des niveaux élevés de FOXA2 et/ou les 746 gènes régulés trouvés ici. Nos résultats soutiennent un mécanisme pour les effets causés par l'erlotinib dans les cellules NSCLC, fournissant ainsi la base moléculaire pour la conception de thérapies plus spécifiques et efficaces pour NSCLC ciblant plusieurs aspects de la chromatine.

  • Open Access

    Erlotinib induces 3D genome rearrangements in lung cancer cells activating tumor suppressor genes through FOXA2-bound Epromoters

    by Guruprasadh Swaminathan, Julio Cordero, Stefan Günther, Johannes Graumann, Thomas Braun, Gergana Dobreva, Guillermo Barreto

    Non-small cell lung cancer (NSCLC) is the most frequent lung cancer (LC). While erlotinib is an epidermal growth factor (EGFR) tyrosine kinase inhibitor (TKI) used in the treatment of NSCLC, it remains unclear how this FDA-approved drug affects the genome. We performed integrative multi-omics studies in human pulmonary carcinoma cells to elucidate the epigenetic mechanisms induced by erlotinib. We identified 746 genes (including 34 tumor suppressor genes, TSG) that were upregulated after treatment with erlotinib or gefitinib (another EGFR-TKI). Interestingly, 45% of the upregulated genes (including 24 TSG) were in broad domains of the euchromatin histone mark H3K4me3, and 63% (including 26 TSG) exhibited reduced levels of the heterochromatin histone mark H3K27me3 after erlotinib treament. Further, H3K27ac-specific chromosome conformation capture-based methods revealed that erlotinib significantly increased number and length of chromatin loops between promoters of upregulated genes and active enhancers. We also detected augmented chromatin accessibility after erlotinib treatment at the promoters of upregulated genes, which correlated with binding of the transcription activator FOXA2. Remarkably, we identified gene clusters that seem to be upregulated by promoters with enhancer activity (Epromoters) enriched with FOXA2. The clinical relevance of our findings was confirmed by data from The Cancer Genome Atlas, showing significantly improved survival outcomes in LC patients with high levels of FOXA2 and/or the 34 TSG found upregulated by erlotinib. Our results establish 3D genome rearrangements as molecular mechanism mediating EGFR-TKI effects in NSCLC cells, supporting the design of more specific therapies for NSCLC targeting different chromatin features.

  • Open Access

    Nuclear microRNA 9 mediates G-quadruplex formation and 3D genome organization during TGF-β-induced transcription

    by Julio Cordero, Guruprasadh Swaminathan, Diana G. Rogel-Ayala, Karla Rubio, Adel Elsherbiny, Samina Mahmood, Witold Szymanski, Johannes Graumann, Thomas Braun, Stefan Günther, et al.

    The dynamics of three-dimensional (3D) genome organization are essential to transcriptional regulation. While enhancers regulate spatiotemporal gene expression, chromatin looping is a means for enhancer-promoter interactions yielding cell-type-specific gene expression. Further, non-canonical DNA secondary structures, such as G-quadruplexes (G4s), are related to increased gene expression. However, the role of G4s in promoter-distal regulatory elements, such as super-enhancers (SE), and in chromatin looping has remained elusive. Here we show that mature microRNA 9 (miR-9) is enriched at promoters and SE of genes that are inducible by transforming growth factor beta 1 (TGFB1) signaling. Moreover, we find that miR-9 is required for formation of G4s, promoter-super-enhancer looping and broad domains of the euchromatin histone mark H3K4me3 at TGFB1-responsive genes. Our study places miR-9 in the same functional context with G4s and promoter-enhancer interactions during 3D genome organization and transcriptional activation induced by TGFB1 signaling, a critical signaling pathway in cancer and fibrosis.


  • Open Access

    Implications in Cancer of Nuclear Micro RNAs, Long Non-Coding RNAs, and Circular RNAs Bound by PRC2 and FUS

    by Guruprasadh Swaminathan, Diana G. Rogel-Ayala, Amine Armich, Guillermo Barreto

    The eukaryotic genome is mainly transcribed into non-coding RNAs (ncRNAs), including different RNA biotypes, such as micro RNAs (miRNAs), long non-coding RNAs (lncRNAs), and circular RNAs (circRNAs), among others. Although miRNAs are assumed to act primarily in the cytosol, mature miRNAs have been reported and functionally characterized in the nuclei of different cells. Further, lncRNAs are important regulators of different biological processes in the cell nucleus as part of different ribonucleoprotein complexes. CircRNAs constitute a relatively less-characterized RNA biotype that has a circular structure as result of a back-splicing process. However, circRNAs have recently attracted attention in different scientific fields due to their involvement in various biological processes and pathologies. In this review, we will summarize recent studies that link to cancer miRNAs that have been functionally characterized in the cell nucleus, as well as lncRNAs and circRNAs that are bound by core components of the polycomb repressive complex 2 (PRC2) or the protein fused in sarcoma (FUS), highlighting mechanistic aspects and their diagnostic and therapeutic potential.


  • Open Access

    3D genome organization during TGFB-induced transcription requires nuclear microRNA and G-quadruplexes

    by Julio Cordero, Guruprasadh Swaminathan, Diana G Rogel-Ayala, Karla Rubio, Adel Elsherbiny, Stefan Guenther, Thomas Braun, Gergana Dobreva, Guillermo Barreto

    Studying the dynamics of three-dimensional (3D) chromatin structure is essential to understand biological processes in the cell nucleus. Recent publications based on integrative analysis of multi-omics studies have provided comprehensive and multilevel insights into 3D genome organization emphasizing its role during transcriptional regulation. While enhancers are regulatory elements that play a central role in the spatiotemporal control of gene expression, chromatin looping has been broadly accepted as a means for enhancer-promoter interactions allowing them to stablish cell-type-specific gene expression signatures. On the other hand, G-quadruplexes (G4s) are non-canonical DNA secondary structures that are both, enriched at promoters and related to increased gene expression. However, the role of G4s in promoter-distal regulatory elements, such as super-enhancers (SE), as well as in 3D genome organization and chromatin looping mediating long-range enhancer-promoter interactions has remained elusive. Here we show that mature microRNA 9 ( miR-9 ) is enriched at promoters and SE of genes that are inducible by tissue growth factor beta 1 (TGFB1) signaling. Further, we found that nuclear miR-9 is required for chromatin features related to increased transcriptional activity, such as broad domains of the euchromatin histone mark H3K4me3 (histone 3 tri-methylated lysine 4) and G4s. Moreover, we show that nuclear miR-9 is required for promoter-super-enhancer looping. Our study places a nuclear microRNA in the same structural and functional context with G4s and promoter-enhancer interactions during 3D genome organization and transcriptional activation induced by TGFB1 signaling, a critical regulator of proliferation programs in cancer and fibrosis.


  • Open Access

    LeukmiR: a database for miRNAs and their targets in acute lymphoblastic leukemia

    by Abdul Rawoof, Guruprasadh Swaminathan, Shrish Tiwari, Rekha A Nair, Lekha Dinesh Kumar

    Acute lymphoblastic leukemia (ALL) is one of the most common hematological malignancies in children. Recent studies suggest the involvement of multiple microRNAs in the tumorigenesis of various leukemias. However, until now, no comprehensive database exists for miRNAs and their cognate target genes involved specifically in ALL. Therefore, we developed ‘LeukmiR’ a dynamic database comprising in silico predicted microRNAs, and experimentally validated miRNAs along with the target genes they regulate in mouse and human. LeukmiR is a user-friendly platform with search strings for ALL-associated microRNAs, their sequences, description of target genes, their location on the chromosomes and the corresponding deregulated signaling pathways. For the user query, different search modules exist where either quick search can be carried out using any fuzzy term or by providing exact terms in specific modules. All entries for both human and mouse genomes can be retrieved through multiple options such as miRNA ID, their accession number, sequence, target genes, Ensemble-ID or Entrez-ID. User can also access miRNA: mRNA interaction networks in different signaling pathways, the genomic location of the targeted regions such as 3′UTR, 5′UTR and exons with their gene ontology and disease ontology information in both human and mouse systems. Herein, we also report 51 novel microRNAs which are not described earlier for ALL. Thus, LeukmiR database will be a valuable source of information for researchers to understand and investigate miRNAs and their targets with diagnostic and therapeutic potential in ALL. Database URL: http://tdb.ccmb.res.in/LeukmiR/